Shenzhen Shankang Pharmaceutical Technology Co., Ltd. has accumulated years of research and development innovation, and has formed an innovative drug delivery system research and development platform with long-acting slow-release implant technology as the core. The company focuses on the innovative application of core technology in addiction treatment, central nervous system disease treatment, tumor treatment, infectious disease treatment and other disease treatment fields, and has formed multiple technology platforms.

      1、 The implant technology platform, representing the product naltrexone hydrochloride implant, has been approved for market by CDE. It uses the sustained-release material poly (D, L -) lactide to encapsulate the drug into microspheres, which are compressed into sheets. Finally, the patented encapsulation technology is used to wrap the naked sheet with a film to further control the drug release rate. The multiple controlled release technology included in the implant has been successfully industrialized and the product has been launched on the market.

      2、 The micro implant technology platform is produced using a continuous production process. The implant is in the shape of a thin rod and does not require surgical implantation. It can be directly injected subcutaneously with a dedicated drug delivery device to complete drug delivery. Multiple pipelines under this technology platform have completed pharmaceutical research and development, as well as animal evaluation, and have entered the IND application stage.

      3、 The auxiliary material synthesis technology platform is an independently built pharmaceutical grade biodegradable polymer material synthesis technology platform, including research and development, pilot testing, and industrialization platforms. It has a GMP quality system management C-level purification production workshop with an annual production capacity of up to 1000kg. Currently, it can synthesize various polymer materials such as PDLLA, PLLA, PLGA, etc.

    Shankang sincerely hopes to exchange research and development of pharmaceutical formulation technology with peers and achieve win-win cooperation.

      Contact: Qu Wei，quwei@sciencare.cn